Grant Publications

Proposal No.  IBD-0016
Principal Investigator:  Paul J. Rutgeerts, M.D., Ph.D.
Applicant Organization:  Katholieke Universiteit Leuven (Belgium)
Project Title:  Study on genetic, immunological and serological predictors of response to anti-TNFα treatment in Crohn's disease
Award Period:  December 1, 2002 – November 30, 2003

Louis E, El Ghoul Z, Vermeire S, Dall'ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Voss M, Van Gossum A, Colombel J-F, Watier H.  Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.  Alimentary Pharmacology & Therapeutics 2004;19:1-9.

Pierik M, Vermeire S, Van Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P.  Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.  Alimentary Pharmacology & Therapeutics 2004;20:303-10.

Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.  Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.  Alimentary Pharmacology & Therapeutics 2005;22:613-26.

Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Joossens S, Bueno de Mesquita M, Rutgeerts P, Vermeire S.  Decision making model for prediction of response to infliximab in luminal and fistulizing Crohn's disease based on a new apoptotic pharmacogenetic index and clinical predictors.  Inflammatory Bowel Diseases 2006;12:870-8.